AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36514060 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (trifluridine and tipiracil) and radioembolization (TARE)
Number of subjects: 21
Study 36514077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Number of subjects: 124
Study 36514077 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 124
Study 36514082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8-week program)
Number of subjects: 0
Study 36514099 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Foot digital tool
Number of subjects: 90
Study 36514106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood red blood cell transfusions (CB-RBCs)
Number of subjects: 0
Study 36514106 — intervention group
Group type: COMPARATOR
Intervention: Standard red blood cell transfusions (adult-RBCs)
Number of subjects: 0
Study 36514143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nafamostat
Number of subjects: 0
Study 36514143 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable dose anticoagulation
Number of subjects: 0
Study 36514195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on continuous glucose monitoring (CGM) data
Number of subjects: 67
Study 36514197 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with AYAs with LFS
Number of subjects: 30
Study 36514248 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine and Z-drugs (BZDRs) use
Number of subjects: 4837
Study 36514248 — intervention group
Group type: COMPARATOR
Intervention: BZDRs use on an as-needed basis
Number of subjects: 4837
Study 36514248 — intervention group
Group type: EXPERIMENTAL
Intervention: BZDRs daily use with increasing doses
Number of subjects: 4837
Study 36514294 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training and behavioral sleep intervention
Number of subjects: 22
Study 36514397 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance hemodialysis (HD)
Number of subjects: 66
Study 36514730 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated palliative care visits (monthly for 3 months)
Number of subjects: 45
Study 36514730 — intervention group
Group type: COMPARATOR
Intervention: Usual nephrology care
Number of subjects: 45
Study 36514847 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-acting aspart
Number of subjects: 0
Study 36514847 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 0
Study 36514850 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg
Number of subjects: 17
Study 36514850 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 17
Study 36514850 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (both doses)
Number of subjects: 17
Study 36514996 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg ITT cohort
Number of subjects: 102
Study 36514996 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg RPR cohort
Number of subjects: 102
Study 36514996 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg RPR cohort
Number of subjects: 102
Study 36515211 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedy movie intervention
Number of subjects: 0
Study 36515211 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation music intervention
Number of subjects: 0
Study 36515211 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine practices)
Number of subjects: 0
Study 36515248 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent depressive symptoms
Number of subjects: 4130
Study 36515248 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset depressive symptoms
Number of subjects: 4130
Study 36515248 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitted depressive symptoms
Number of subjects: 4130
Study 36515248 — intervention group
Group type: COMPARATOR
Intervention: No depressive symptoms
Number of subjects: 4130
Study 36515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4015
Study 36515247 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 4015
Study 36515484 — intervention group
Group type: EXPERIMENTAL
Intervention: JA-CASS (juvenile arthritis child acceptable symptom state)
Number of subjects: 239
Study 36515484 — intervention group
Group type: EXPERIMENTAL
Intervention: JA-PASS (juvenile arthritis parent acceptable symptom state)
Number of subjects: 239
Study 36515491 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal infusion of bupivacaine combined with low-dose fentanyl
Number of subjects: 36
Study 36515491 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 36
Study 36515544 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat Mesylate (DWJ1248)
Number of subjects: 0
Study 36515544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36515663 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-371797
Number of subjects: 12
Study 36515673 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) group
Number of subjects: 66
Study 36515673 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine laparoscopic white-light imaging)
Number of subjects: 66
Study 36515785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity measured by the McGill Pain Questionnaire
Number of subjects: 190
Study 36515785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-specific distress symptoms measured by the Impact of Events Scale-Revised
Number of subjects: 190
Study 36515785 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and functional well-being measured by the Functional Assessment of Cancer Therapy-General
Number of subjects: 190
Study 36515808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection with total mesorectal excision (TME)
Number of subjects: 49
Study 36515868 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally supervised home exercise group (group 1)
Number of subjects: 75
Study 36515868 — intervention group
Group type: COMPARATOR
Intervention: Home exercise group (group 2)
Number of subjects: 75
Study 36515868 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 75
Study 36515888 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic BC30 with a 20-g dose of a blend of rice and pea protein
Number of subjects: 30
Study 36515888 — intervention group
Group type: COMPARATOR
Intervention: Control group (20-g dose of a blend of rice and pea protein without BC30)
Number of subjects: 30
Study 36515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital prosthetic socket fabricated using digital shape capture with a 3D scanner, CAD, and 3D printing
Number of subjects: 11
Study 36515905 — intervention group
Group type: COMPARATOR
Intervention: Traditionally handcasted manually fabricated socket
Number of subjects: 11
Study 36515906 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed transtibial amputation
Number of subjects: 1
Study 36515906 — intervention group
Group type: COMPARATOR
Intervention: Limb salvage
Number of subjects: 1
Study 36515976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding TAVI
Number of subjects: 4762
Study 36515976 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 4762
Study 36515976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding TAVI (in patients with smaller annuli, 23 mm diameter or smaller)
Number of subjects: 4762
Study 36515976 — intervention group
Group type: COMPARATOR
Intervention: Surgery (in patients with smaller annuli, 23 mm diameter or smaller)
Number of subjects: 4762
Study 36515976 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD
Number of subjects: 4762
Study 36515980 — intervention group
Group type: EXPERIMENTAL
Intervention: OmniGraf monitoring in conjunction with medication-related symptom burden (MRSB) monitoring
Number of subjects: 2000
Study 36515980 — intervention group
Group type: EXPERIMENTAL
Intervention: OmniGraf monitoring
Number of subjects: 2000
Study 36515980 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 2000
Study 36515984 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-day self-guided intervention (SGI) on stress-coping (Intellect)
Number of subjects: 321
Study 36515984 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 321
Study 36515992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring data sharing and JITAIs-On
Number of subjects: 30
Study 36515992 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose monitoring data sharing and JITAIs-Off
Number of subjects: 30
Study 36516076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone at a daily dose of 12.5 or 25 mg
Number of subjects: 13523
Study 36516076 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide at a daily dose of 25 or 50 mg
Number of subjects: 13523
Study 36516076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 13523
Study 36516076 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 13523
Study 36516082 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial vaccination cohort (210 patients)
Number of subjects: 327
Study 36516082 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination cohort (117 patients)
Number of subjects: 327
Study 36516082 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving B-cell-directed therapy
Number of subjects: 327
Study 36516082 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccinations
Number of subjects: 327
Study 36516082 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial vaccination cohort
Number of subjects: 327
Study 36516082 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination cohort
Number of subjects: 327
Study 36516078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26-MVA group
Number of subjects: 2801
Study 36516078 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV group
Number of subjects: 2801
Study 36516078 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-booster group
Number of subjects: 2801
Study 36516078 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2801
Study 36516090 — intervention group
Group type: EXPERIMENTAL
Intervention: B-VEC
Number of subjects: 31
Study 36516090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 36516159 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural livelihood and finance intervention including training and microfinance loan for purchasing farming implements.
Number of subjects: 54
Study 36516159 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 54
Study 36516343 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine (0.5-0.75 mg/kg)
Number of subjects: 66
Study 36516644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-BESTest total score in mTBI group
Number of subjects: 90
Study 36516644 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive postural control subdomain in mTBI group
Number of subjects: 90
Study 36516644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory orientation subdomain in mTBI group
Number of subjects: 90
Study 36516644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic gait subdomain in mTBI group
Number of subjects: 90
Study 36516644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory postural adjustments subdomain in mTBI group
Number of subjects: 90
Study 36516851 — intervention group
Group type: EXPERIMENTAL
Intervention: Social ballroom dancing
Number of subjects: 25
Study 36516851 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 25
Study 36517088 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC tracheal tube
Number of subjects: 104
Study 36517088 — intervention group
Group type: COMPARATOR
Intervention: WR tracheal tube
Number of subjects: 104
Study 36517097 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise (BE) intervention; 4-week self-administered program
Number of subjects: 72
Study 36517097 — intervention group
Group type: COMPARATOR
Intervention: Usual care and pain information booklet
Number of subjects: 72
Study 36517099 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator Programme (Critical Time Intervention case management programme) for 90 days after hospital discharge
Number of subjects: 640
Study 36517099 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 640
Study 36517235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 or 15 mg BID for 12 weeks
Number of subjects: 300
Study 36517235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 36517235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 5 mg BID for 1 week, 10 mg BID for 1 week
Number of subjects: 300
Study 36517235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin (various dosages)
Number of subjects: 300
Study 36517284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone, dosage and duration not available
Number of subjects: 0
Study 36517284 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36517335 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D transesophageal echocardiogram with live multiplanar reconstruction
Number of subjects: 0
Study 36517335 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2D transesophageal techniques
Number of subjects: 0
Study 36517395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodic stimulation in the transverse plane
Number of subjects: 15
Study 36517395 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal cathodic stimulation
Number of subjects: 15
Study 36517395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique stimulation
Number of subjects: 15
Study 36517469 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of BNT162b2
Number of subjects: 0
Study 36517479 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the fornix
Number of subjects: 46
Study 36517479 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the circuit of Papez and stria terminalis
Number of subjects: 46
Study 36517479 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal stimulation site at the interface between Papez and stria terminalis
Number of subjects: 46
Study 36517479 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulating specific distributed brain networks related to memory
Number of subjects: 46
Study 36517740 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) monitoring with two decision-making PCT-based algorithms
Number of subjects: 107
Study 36517740 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antibiotic therapy without PCT monitoring)
Number of subjects: 107
Study 36517740 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) monitoring
Number of subjects: 107
Study 36517745 — intervention group
Group type: EXPERIMENTAL
Intervention: D-SCOPE program (6-step detection and prevention program)
Number of subjects: 869
Study 36517767 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (140 mg)
Number of subjects: 32
Study 36517849 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 31
Study 36517849 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to reduce stigma affecting PWH on MMT
Number of subjects: 31
Study 36517856 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa enzyme replacement therapy
Number of subjects: 20
Study 36517865 — intervention group
Group type: EXPERIMENTAL
Intervention: AV-GBM-1 vaccine administration
Number of subjects: 63
Study 36517899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure (BP) variability
Number of subjects: 0
Study 36517899 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative SBP difference > -5 mmHg
Number of subjects: 0
Study 36517899 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis adjusted for age, sex, presence of diabetes, and 24-h ambulatory SBP
Number of subjects: 0
Study 36517906 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-enabled real-time echocardiographic assessment of left ventricular ejection fraction (LVEF)
Number of subjects: 95
Study 36517906 — intervention group
Group type: COMPARATOR
Intervention: Manual measurements by experts
Number of subjects: 95
Study 36517997 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth scaling and root planing (FM-SRP)
Number of subjects: 40
Study 36517997 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing (Q-SRP)
Number of subjects: 40
Study 36518248 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-guided therapy
Number of subjects: 104
Study 36518253 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor letrozole (2.5mg/day; n=11)
Number of subjects: 22
Study 36518253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone (1mg/kg/every 4 weeks; n=11)
Number of subjects: 22
Study 36518364 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS-2 total scores for girls
Number of subjects: 384
Study 36518364 — intervention group
Group type: COMPARATOR
Intervention: SRS-2 total scores for boys
Number of subjects: 384
Study 36518364 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SRS-2 total score and IQ for girls
Number of subjects: 384
Study 36518606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counseling and navigation (TCN)
Number of subjects: 0
Study 36518606 — intervention group
Group type: COMPARATOR
Intervention: Targeted print brochure
Number of subjects: 0
Study 36518606 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36518723 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for SCD risk stratification and management
Number of subjects: 1491
Study 36518723 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at SCD risk stratification and management visit
Number of subjects: 1491
Study 36518723 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting ICD indication criteria
Number of subjects: 1491
Study 36518723 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1491
Study 36518723 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall referral and ICD implantation rates
Number of subjects: 1491
Study 36518729 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled, simultaneous doses of acetaminophen, celecoxib, and pregabalin; oxycodone 5 mg as needed for breakthrough pain.
Number of subjects: 100
Study 36518729 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and oxycodone 5 mg/acetaminophen 325 mg as needed for pain (Control).
Number of subjects: 100
Study 36518770 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI weaning
Number of subjects: 0
Study 36518770 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36518987 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone levels ≥7.8 ng/ml
Number of subjects: 402
Study 36518987 — intervention group
Group type: COMPARATOR
Intervention: Serum progesterone levels <7.8 ng/ml
Number of subjects: 402
Study 36519118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 5
Study 36519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP/NX)
Number of subjects: 272
Study 36519188 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 272
Study 36519287 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week concurrent exercise program
Number of subjects: 150
Study 36519287 — intervention group
Group type: COMPARATOR
Intervention: Counseling (control group)
Number of subjects: 150
Study 36519326 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis arm
Number of subjects: 152
Study 36519326 — intervention group
Group type: COMPARATOR
Intervention: SOC arm
Number of subjects: 152
Study 36519326 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis arm (subgroup with antithymocyte globulin)
Number of subjects: 152
Study 36519326 — intervention group
Group type: COMPARATOR
Intervention: SOC arm (subgroup with antithymocyte globulin)
Number of subjects: 152
Study 36519325 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-azacitidine
Number of subjects: 39
Study 36519451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive goal SBP <120 mm Hg
Number of subjects: 7860
Study 36519451 — intervention group
Group type: COMPARATOR
Intervention: Standard goal SBP <140 mm Hg
Number of subjects: 7860
Study 36519564 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of speedometer during colonoscopy
Number of subjects: 166
Study 36519564 — intervention group
Group type: COMPARATOR
Intervention: No speedometer during colonoscopy
Number of subjects: 166
Study 36519620 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 2278
Study 36519620 — intervention group
Group type: COMPARATOR
Intervention: Early paracetamol treatment
Number of subjects: 2278
Study 36519620 — intervention group
Group type: COMPARATOR
Intervention: Late paracetamol treatment
Number of subjects: 2278
Study 36519620 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol combined with ibuprofen
Number of subjects: 2278
Study 36519749 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance nivolumab SOC (480 mg 4 weekly)
Number of subjects: 160
Study 36519749 — intervention group
Group type: COMPARATOR
Intervention: Extended interval (480 mg 8 weekly)
Number of subjects: 160
Study 36519767 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered care intervention for well-nourished participants
Number of subjects: 134
Study 36519767 — intervention group
Group type: COMPARATOR
Intervention: Control group for well-nourished participants
Number of subjects: 134
Study 36519767 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered care intervention for poorly-nourished participants
Number of subjects: 134
Study 36519767 — intervention group
Group type: COMPARATOR
Intervention: Control group for poorly-nourished participants
Number of subjects: 134